化学
预酸化
药品
喹啉
药理学
过氧化物酶体增殖物激活受体
消炎药
立体化学
酶
生物化学
有机化学
受体
医学
作者
Carlos Villarroel-Vicente,Ainhoa García,Khamis Zibar,María A. Schiel,Jordi Ferri,Nathalie Hennuyer,Ricardo Daniel Enriz,Bart Staels,Diego Cortés,Nuria Cabedo
标识
DOI:10.1016/j.bmcl.2024.129770
摘要
We have previously reported the total synthesis and structure-activity relationships (SAR) of 2-prenylated benzopyrans with PPAR agonist activity. Herein, we have described the synthesis and PPAR activity of 2-prenylated benzopyrans and 2-prenylated quinolines. The benzopyran nucleus was generated via enamine-catalyzed Kabbe condensation, and the quinoline nucleus via Friedländer condensation. Results demonstrated that both benzopyran (5a) and quinoline (4b) derivatives bearing a γ,δ-unsaturated ester displayed a pan-PPAR agonism. They were full PPARα agonists, but showed different preferences for PPARγ and PPARβ/δ activation. It was noteworthy that quinoline 4b displayed full hPPARα activation (2-fold than WY-14,643), weak PPARβ/δ and partial PPARγ activation. In addition, quinoline 4b showed anti-inflammatory effects on macrophages by reducing LPS-induced expression of both MCP-1 and IL-6. Therefore, 4b emerges as a first-in-class promising hit compound for the development of potential therapeutics aimed at treating metabolic syndrome, metabolic dysfunction-associated fatty liver disease (MAFLD), and its associated cardiovascular comorbidities.
科研通智能强力驱动
Strongly Powered by AbleSci AI